Studien

PETPLAN

PETPLAN
Status: aktiv
Optimierung der Strahlentherapieplanung von  Patienten mit inoperablen lokal fortgeschrittenen nicht-kleinzelligen Bronchialkarzinomen mittels F-18-FDG – Prospektive randomisierte multizentrische Therapieoptimierungsstudie

MF1001
Status: geplant
An open-label,randomized,controlled study to determine efficacy of NanoTherm therapy, NanoTherm therapy + radiotherapy versus radiotherapy in recurrent glioblastoma

PRESENT
Status: geplant
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression mit NeuVAXTM  Treatment

CBKM120F2202  BELLE4
Status: geplant
A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2negative inoperabel locally advanced or metastatic breast cancer, with or without PI3K pathway activation    

C25001
Status: aktiv
A randomized,, open-label, phase 3 trial of brentuximab vedotin (SGN-35) versus physician`s choice (methotrexate or bexaretene) in patients with CD30-positive T-cell lymphoma

PCYC-1121-CA
Status: geplant
A multicenter,  open-label, phase II  study of bruton`s tyrosine kinase (BTK) inhibitor, Ibrutinib, in subjects with relapsed/refractory marginal zone lymphoma

BO21223
Status: geplant
A multicenter, phase II, open-label, randomized study in previosly untreated patients with advanced indolent non-hodgkin`s lymphoma evaluating the benefit of GA101(RO5072759)plus chemotherapy compared with rituximab plus chemotherapie followed by GA101 or rituximab maintenance therapy in responders

AFM11
Status: geplant
A pharmacodynamically-guided dose escalation phase I study to assess the safety of AFM11 (recombinant antibody construct against hum CD19 und CD3) in patients with prelapsed and/or refractory CD19 positive B-cell NHL and adult B-precursor ALL

DSHNHL 2009-1 OPTIMAL>60
Status: geplant
Verbesserung der Therapieergebnisse und Verminderung der Nebenwirkungen bei älteren Patienten mit CD20+ aggressiven B-Zell-Lymphomen durch eine optimierte Gabe des monoklonalen Antikörpers Rituximab, Ersatz von konventionellenm durch liposomales Vincristin und FDG-PET basierter Therapiereduktion

WA28119
Status: geplant
A phase III, multicenter, randomized, double-blind placebo-controlled study to assess the efficacy and safety of tocilizumab in subjets with giant cell arteritis ("trial")      

PCI-32765MCL3001
Status: beendet
A Multicenter, Open-Label, Phase 2 Study of the Bruton`s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma          

HD 18
Status: aktiv
Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratefizierung mittels FDG-PET

EuroNET-PHL-C1
Status: aktiv
First international Inter-Group Study for classical Hodgkin´s Lymphoma in Children and Adolescents

PETAL
Status: aktiv
Positronen-Emissionstomographie-gesteuerte Therapie agressiver Non-Hodgkin-Lymphome

Bolero-3
Status: beendet
A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination with Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer

NeoPHOEBE (aktiv)
Status: aktiv
Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer